Genome-Wide Analysis of DNA Methylation and the Gene Expression Change in Lung Cancer  by Kwon, Yong-Jae et al.
ORIGINAL ARTICLE
Genome-Wide Analysis of DNA Methylation and the Gene
Expression Change in Lung Cancer
Yong-Jae Kwon, PhD,* Seog Joo Lee, MSc,* Jae Soo Koh, MD, PhD,† Sung Han Kim, PhD,‡
Hae Won Lee, MD,§ Moon Chul Kang, MD,§ Jae Bum Bae, PhD, Young-Joon Kim, PhD, and
Jong Ho Park, MD, PhD§
Introduction: The recent DNA methylation studies on cancers have
revealed the necessity of profiling an entire human genome and not
to restrict the profiling to specific regions of the human genome. It
has been suggested that genome-wide DNA methylation analysis
enables us to identify the genes that are regulated by DNA methyl-
ation in carcinogenesis.
Methods: So, we performed whole-genome DNA methylation anal-
ysis for human lung squamous cell carcinoma (SCC), which is
strongly related with smoking. We also performed microarrays using
21 pairs of normal lung tissues and tumors from patients with SCC.
By combining these data, 30 hypermethylated and down-regulated
genes, and 22 hypomethylated and up-regulated genes were se-
lected. The gene expression level and DNA methylation pattern
were confirmed by semiquantitative reverse-transcriptase polymer-
ase chain reaction and pyrosequencing, respectively.
Results: By these validations, we selected five hypermethylated and
down-regulated genes and one hypomethylated and up-regulated
gene. Moreover, these six genes were proven to be actually regu-
lated by DNA methylation by confirming the recovery of their DNA
methylation pattern and gene expression level using a demethylating
agent. The DNA methylation pattern of the CYTL1 promoter region
was significantly different between early and advanced stages of
SCC.
Conclusion: In conclusion, by combining the whole-genome
DNA methylation pattern and the gene expression profile, we
identified the six genes (CCDC37, CYTL1, CDO1, SLIT2, LMO3,
and SERPINB5) that are regulated by DNA methylation, and we
suggest their value as target molecules for further study of SCC.
Key Words: Lung cancer, DNA methylation, Pyrosequencing,
Microarray.
(J Thorac Oncol. 2012;7: 20–33)
The clinical, pathologic, and genomic characteristics oflung cancer are very diverse, and the most decisive
treatment for it is to perform a curative resection at its earliest
detection. Nevertheless, lung cancer still has been reported to
be one of the most common malignant diseases with a poor
prognosis.1 Therefore, to increase the cure and survival rates,
developing various diagnostic and treatment methods by
using genomic studies of lung cancer might improve this
situation. In this context, there have been various genomic
studies of lung cancer for the last few decades, but any
brilliant solution has not been found. Accordingly, epigenetic
studies represented by DNA methylation and histone modi-
fication have been receiving much attention. This is because
DNA methylation is related to the gene expression at the very
early stage of tumorigenesis and DNA methylation is a
reversible reaction.2,3 It was found that abnormal DNA meth-
ylation of specific genes can cause various cancers to have a
different response to chemotherapeutic drugs.4 For example,
the hypermethylation of the MGMT gene, and this gene is
related to DNA repair, decreases the sensitivity to alkylating
agents in glioma patients by lowering the DNA repair func-
tion, and the hypermethylation of the WRN gene (DNA
helicase) increases the sensitivity to the topoisomerase inhib-
itor irinotecan in patients with colorectal cancer.5–8 Similarly,
analyzing the DNA methylation of individual genes could be
crucial index for selective treatment. Many genes such as
APC, CADM1, CDH1, CDH13, CDKN2A/p14, CDKN2A/
p16, DAPK, FHIT, GSTP1, MGMT, MLH1, and RASSFA1
have been proven to be hypermethylated in non-small cell
lung cancer (NSCLC).1 Despite these achievements, there has
been a limitation for not covering the whole genome. So,
whole-genome scale analyses for a comprehensive under-
standing of DNA methylation have recently been performed.
For example, the MeDIP-seq analysis with breast cancer cell
lines has allowed us to understand the abnormal DNA meth-
ylation pattern of various genes involved in the development
of breast cancer, and MeDIP-tilling array with testicular germ
cell tumor has enabled us to identify the epigenetically
regulated genes and ncRNAs.9,10 DNA methylation analyses
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of lung cancer on a whole-genome scale have also been
tried.11 Although similar studies have been conducted on
renal cell carcinoma and breast cancer,12,13 our approach is
the first trial to combine the genome-wide methylation pattern
and the gene expression profile to identify the genes regulated
by DNA methylation in squamous cell carcinoma (SCC).
Herein, we examined the DNA methylation of SCC of the
lung on a whole-genome scale by using the methylated CpG
island recovery assay (MIRA) and an Illumina Genome
Analyzer (GA), which is a next-generation sequencer. The
MIRA technique we used herein was recently developed, and
it has the advantage that MBD3L1 can enhance the specific
recognition of methylated CpG dinucleotides by the MBD2b
protein.14–16 The Illumina GA, which sequences methylated
DNA, seems to measure cytosine methylation on a genome-
wide scale more sensitively than the chip-based methods.17
We used tissue samples of SCC of the lung, and this malig-
nancy is strongly related to smoking.18,19 DNA methylation
data were obtained by the technique mentioned earlier, and
then we analyzed this data combined with the gene expres-
sion profile. Therefore, this study has implications for using
a whole-genome DNA methylation analysis to find the genes
in lung cancer that are regulated by DNA methylation.
PATIENTS AND METHODS
Patients and Tissue Samples
We used a total of 50 tissue samples from 50 patients
with lung cancer who underwent surgery at Korea Cancer
Center Hospital without preoperative treatment. The histol-
ogy of all the specimens was SCC. The mean age of patients
was 62.6 years (42–82 years), and 48 persons (96%) had the
history of smoking. We used another 21 samples for the
microarray, three samples for the whole-genome DNA meth-
ylation assay, and 30 samples for semiquantitative reverse-
transcriptase polymerase chain reaction (RT-PCR) and pyro-
sequencing. All the specimens were stored in liquid nitrogen
immediately after surgical resection. The clinical information
was obtained from the medical records. The pathologic stage
was judged according to the criteria of the American Joint
Committee on Cancer (7th edition). The Institutional Review
Board of Korea Cancer Center Hospital approved this study.
Microarray
Total RNA from the frozen tissues of patients with lung
cancer was isolated using Trizol (Invitrogen, Carlsbad, CA)
as per manufacturer’s instruction. Two micrograms of RNA
was used to produce cRNA, which was hybridized to
CodeLink Expression Arrays. We used the fold change of the
average gene expression value for the definition criteria.
When log2 (T  gene expression level of SCC/N  gene
expression level of normal lung tissue) is above 1 or below
1, we regarded this as up-regulation or down-regulation,
respectively.
Whole-Genome DNA Methylation Analysis by
the GA II (Illumina Inc., San Diego, CA)
We purified the genomic DNA from the normal lung
and tumor tissue of three patients with SCC by using the
DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA). Three
genomic DNAs from each group (normal and tumor) were
then pooled at the same concentration. MIRA was carried out
as described previously.14 The GST-tagged MBD2b and His-
tagged MBD3L1 proteins were prepared as described previ-
ously.15 We used 10 ng of the DNA obtained from MIRA for
the Illumina GA sequencing. Sequence tags were mapped to
the human genome (the University of California Santa
Cruz [UCSC] hg18 database based on the NCBI Build 36.1
assembly) using the Solexa Analysis Pipeline (version
0.3.0). The sequenced reads of 34 bp (excluding the first
and last nucleotides) were obtained. We converted the output
to browser extensible data files for visualization in the UCSC
genome browser (http://genome.ucsc.edu). The methylation
score (MES) was calculated as the log2 of (target read
number/target size)/(total read number/genome size). To
evaluate the measured hypermethylation or hypomethylation
of the promoters, we introduced one arbitrary term called the
difference of MES (dMES) (dMES [SCC MES] [normal
MES]). Using this term, we regarded the genes of dMES
more than 1.5 as hypermethylated genes and the genes of
dMES less than 1.5 as hypomethylated genes.
Semiquantitative RT-PCR
We selected the hypermethylated and down-regulated
genes and the hypomethylated and up-regulated genes by
combining the microarray data with whole-genome DNA
methylation pattern. Then, we examined the expression levels
of selected genes by semiquantitative RT-PCR. The total
RNA was isolated from 30 SCC frozen tissues using the
RNeasy Mini Kit (Qiagen Science, MD) and following the
manufacturer’s protocol. The concentration of RNA was
measured by spectrophotometry. A total of 1 g RNA from
each sample was subjected to reverse transcription to produce
single-stranded complementary DNAs with using an oligo dT
primer (Bioneer, Seoul, Korea) and Superscript II (Invitro-
gen). Semiquantitative RT-PCR experiments were carried out
with the following sets of synthesized primers that were
specific to 52 representative genes. They include 30 hyper-
methylated and down-regulated genes and 22 hypomethy-
lated and up-regulated genes in SCC. We used GAPDH-
specific primers as an internal control. The PCR reactions
were optimized for the number of cycles and the annealing
temperature to obtain a DNA band of the exact product size.
Pyrosequencing
The genomic DNA was isolated from 20 frozen SCC
tissues and two SCC cell lines (HCC-95 and HCC-1588)
using the DNeasy Blood & Tissue Kit (Qiagen, Hilden,
Germany) and from 110 SCC formalin-fixed and paraffin-
embedded tissues using the QIAamp DNA FFPE Tissue Kit
(Qiagen, Hilden, Germany), per the manufacturer’s instruc-
tions. The DNA was quantified using a NanoDrop ND-100
Spectrophotometer (Thermo Fisher Scientific, MA) before
bisulfite treatment. The DNA (2 g/reaction) was bisulfite
treated using the EpiTect Bisulfite Kit (Qiagen, Hilden, Ger-
many), according to the manufacturer’s instructions. The
bisulfite-treated DNA was eluted in 20 l of the manufactur-
er’s Elution Buffer (20 l final volume). The bisulfite-
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converted sequences were examined by using Assay Design
Software version 1.0.6 (Biotage, Uppsala, Sweden). We con-
sidered that the promoter region of each gene is 1000 bp
upstream and 500 bp downstream from the transcription start
site. Each 50 l PCR contained 2.5 mM MgCl2, 0.2 mM
deoxyribonucleotide triphosphate, 0.05 U/l EF-TaqDNA poly-
merase (Solgent, Korea) and 0.2 M each of the forward and
reverse primers (Table 4), and 200 ng of bisulfite-treated DNA.
All the primers were synthesized at Bioneer (Seoul, Korea).
In this study, we used the following PCR cycling conditions.
One cycle of 95°C for 2 minutes for the initial denaturation
steps was followed by 55 cycles of denaturation at 95°C for
30 seconds, various annealing temperatures (55–63°C) for 30
seconds, and then extension at 72°C for 30 seconds. PCR was
terminated after a final cycle at 72°C for 5 minutes. Pyrose-
quencing was performed according to the manufacturer’s
instructions.
Demethylation Test In Vitro
The human SCC cell lines HCC-1588 and HCC-95
were maintained in RPMI 1640 supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 100 IU/ml peni-
cillin, and 100 g/ml streptomycin at 37°C in an atmosphere
of 5% CO2 in air. The other human SCC cell lines Calu-1 and
SK-MES-1 were maintained in ATCC-formulated McCoy’s
5a Medium Modified Catalog No. 30-2007 and Eagle’s Min-
imum Essential Medium, Catalog No. 30-2003 supplemented
with 10% heat-inactivated FBS, 100 IU/ml penicillin, and
100 g/ml streptomycin at 37°C in an atmosphere of 5% CO2
in air, respectively. Another human SCC cell line SW900 was
maintained in Leibovitz’s L-15 Medium, Catalog No. 30-
2008 supplemented with 10% heat-inactivated FBS, 100
IU/ml penicillin, and 100 g/ml streptomycin at 37°C in
100% air; 2  106 cells of each cell line were treated with 20
M 5-aza-2-deoxycytidine (Sigma, St. Louis, MO), and they
were grown for 4 days. The gene expression and DNA
methylation pattern before and after treatment with demethy-
lating agent were examined by semiquantitative RT-PCR and
pyrosequencing, respectively. Cell lines HCC-1588 and
HCC-95 were obtained from Korean Cell Line Bank on
March 23, 2010. The other cell lines Calu-1, SK-MES-1 and
SW900 were obtained from ATCC on May 5, 2011. The cell
lines have been characterized using DNA fingerprinting anal-
ysis by the cell bank.
Statistical Analysis
Student’s t tests were used to examine the difference of
the DNA methylation levels between the normal tissues and
the SCC tissues. One-way analysis of variance was applied to
determine the correlation of the DNA methylation level with
the SCC stages, and p values less than 0.05 were regarded as
statistically significant. The statistical analysis was done
using GraphPad Prism software version 5.03 for Windows
(San Diego, CA, www.graphpad.com).
RESULTS
Selection of Candidate Genes
In an effort to find the genes regulated by DNA meth-
ylation in SCC, we performed a microarray and a genome-
wide DNA methylation sequencing. All the steps to identify
the target genes are briefly depicted in Figure 1. We selected
52 candidate genes after combining the gene expression data
with the whole-genome DNA methylation pattern as listed in
Table 1. At first, we chose 26 genes, including CDO1, with
the criteria of a dMES more than 1.5 and a log2 (T/N) less
than1, and 17 genes, including SERPINB5, with the criteria
of a dMES less than 1.5 and a log2 (T/N) more than 1.
Second, we included two genes (CCDC37 and DLEC1) that
were extremely hypermethylated (dMES 2.5) and five
genes, including ELMO3, that were extremely hypomethy-
lated (dMES 2.1) in this screening list regardless of the
change of gene expression. Finally, the highly down-regu-
lated genes MYH2 and DNM3 (log2 (T/N) 2.5) were
added to the list. In this screening procedure, we focused on
DNA methylation of the promoter region. Moreover, we tried
to screen all the promoters without consideration of the
existence of CpG islands because it was reported that the
promoters not having CpG island also have an effect on gene
expression.20
The Genes Selected by the Validation Steps:
CCDC37, CYTL1, CDO1, LMO3, SLIT2, and
SERPINB5
We attempted to verify the gene expression pattern of
52 genes by performing semiquantitative RT-PCR with using
another 30 SCC tissue samples listed in Table 2. We found 12
down-regulated genes and one up-regulated gene in more
than 57% of the SCC samples, as listed in Table 3. From
screening to validation, we used one gene, DLEC1, as a
positive control to improve the reliability. As DLEC1 had
been reported to be down-regulated by DNA methylation,21
FIGURE 1. Schematic diagram showing all the steps to
identify the target genes. The outline of the procedures to
find the genes regulated by DNA methylation in squamous
cell carcinoma (SCC). Two independent experiments (whole-
genome DNA methylation assay and microarray) were per-
formed, and then the results were combined. According to
this flowchart, we selected the target genes from the whole-
genome scale combining assay, and we confirmed the data
of the clinical samples. At the end, we can obtain the clinical
meanings by statistical analysis.
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TABLE 3. Down- or Up-Regulated Genes in 57% of the
SCC Tissue Samples
Classification No. Gene
The Number of Samples
Down- or Up-Regulated
Hypermethylation 1 CCDC37 17 (57%)
2 DLEC1 15 (50%)
3 MYH2 18 (60%)
6 CDO1 20 (67%)
8 PPP1R14A 22 (73%)
9 SLIT2 22 (73%)
13 CYTL1 18 (60%)
17 NID1 19 (63%)
19 PGC 25 (83%)
22 LMO3 23 (77%)
25 HOPX 17 (57%)
27 KANK2 20 (67%)
28 COL13A1 23 (77%)
Hypomethylation 18’ SERPHINB5 26 (87%)
Thirty tissue samples were used for semiquantitative RT-PCR, and the number
(ratio) of tissue samples where each gene was down- or up-regulated is shown.
RT-PCR, reverse-transcriptase polymerase chain reaction; SCC, squamous cell carcinoma.
TABLE 1. Selected Genes by Combining the Microarray
Data with the Whole-Genome DNA Methylation Patterns
Classification No. Gene dMES(T-N) Log2(T/N)
Hypermethylation 1 CCDC37 3.441251143 0.438497777
2 DLEC1 2.797680143 (-)
3 MYH2 1.215407714 3.987329902
4 DNM3 1.311622857 2.665170126
5 PAX9 3.29980875 1.108395547
6 CDO1 3.226884714 1.985933328
7 HIST1H3A 2.782833571 1.264196556
8 PPP1R14A 2.5877785 1.440936626
9 SLIT2 2.489663125 1.817988624
10 CTSE 2.421966571 1.154048118
11 ADAM33 2.300755429 1.221087063
12 KLRC4 2.130859375 1.451254932
13 CYTL1 2.11463975 1.165674222
14 AGTR1 2.01972575 1.356755098
15 CLTCL1 2.009838863 1.023127859
16 RGS5 2.005905988 1.434346574
17 NID1 1.998283186 1.272255513
18 TCAP 1.95850975 1.012605722
19 PGC 1.91369675 2.417429465
20 ASTN2 1.904766 2.116127773
21 TMEM146 1.863058571 1.029065264
22 LMO3 1.845670163 1.188834946
23 SLC1A2 1.8171925 1.129283017
24 APOB48R 1.781701143 1.809420667
25 HOPX 1.757325125 1.099664166
26 GUCA2B 1.750145286 1.17527637
27 KANK2 1.736910125 1.182291311
28 COL13A1 1.728430757 1.470238996
29 CA10 1.662334943 2.829902911
30 HIST1H1B 1.622941043 2.52113352
Hypomethylation 1’ KRTCAP3 3.2628938 1.552826764
2’ NETO2 2.797227 1.125125323
3’ ELMO3 2.550139125 0.859621462
4’ MT1B 2.521117188 0.832941395
5’ NSDHL 2.43747225 1.037793283
6’ COL1A1 2.350527429 0.84662518
7’ LASP1 2.237798571 1.026014302
8’ PSMA6 2.235948875 0.964107805
9’ ADSSL1 2.182571286 1.172602594
10’ EDN2 2.18182875 3.577795253
11’ CBS 2.152533629 0.854992104
12’ CCL7 2.149588125 1.128776661
13’ PDCL2 2.027630429 4.248027683
14’ SPC25 2.970506286 2.701452195
15’ PAGE4 2.1768414 3.211556392
16’ GBX2 1.637031629 2.88765218
17’ PRIM1 1.64499125 2.185488422
18’ SERPINB5 1.784078125 4.121717307
19’ CDCA5 1.820698857 2.514666762
20’ SLC35F3 1.99832255 2.02506441
21’ KCNC1 1.952510671 2.427335724
22’ HOXD11 1.83193375 2.72750794
Thirty genes that were hypermethylated and down-regulated and 22 genes that were
hypomethylated and up-regulated are presented. Arbitrary term called dMES means (dMES 
SCC MES  normal MES), and the fold-change in the expression levels was calculated by
log2 (tumor/normal lung). The expression level of each gene in normal lung and tumor was
represented by the average of 21 normal tissues and tumors, respectively. The symbol (-) means
that the gene expression data for DLEC1 in the microarray do not exist.
SCC, squamous cell carcinoma.
TABLE 2. Clinical Data of the Patients Whose Tissues were
Used for RT-PCR and Pyrosequencing
No. Gender
Age
(yr)
Smoking (Pack
per Year) Cell Type Stage
1 M 78 75 SCC T2aN0M0, IB
2 M 76 40 SCC T2aN0M0, IB
3 M 72 20 SCC T2bN0M0, IIA
4 M 68 150 SCC T2aN0M0, IA
5 M 69 35 SCC T2bN0M0, IIA
6 M 65 40 SCC T2aN0M0, IB
7 M 70 40 SCC T2aN0M0, IB
8 M 67 45 SCC T1bN1M0, IIA
9 M 61 40 SCC T1aN1M0, IIA
10 M 60 50 SCC T2aN1M0, IIA
11 M 58 30 SCC T2aN1M0, IIA
12 M 73 25 SCC T2aN1M0, IIA
13 M 53 60 SCC T2aN1M0,IIA
14 M 47 35 SCC T2aN1M0, IIA
15 M 84 60 SCC T2aN2M0, IIIA
16 M 63 30 SCC T2aN2M0, IIIA
17 M 66 20 SCC T3 N2M0, IIIA
18 M 68 60 SCC T2aN2M0, IIIA
19 M 59 60 SCC T2aN2M0, IIIA
20 M 62 80 SCC T2aN2M0, IIIA
21 M 68 40 SCC T2bN2M0, IIIA
22 M 70 20 SCC T4N0M0, IIIA
23 M 65 10 SCC T2aN1M0, IIA
24 M 47 20 SCC T2aN0M0, IB
25 M 64 0 SCC T4N1M0, IIIA
26 M 71 60 SCC T2aN2M0, IIIA
27 M 58 40 SCC T3N0M0, IIB
28 M 74 50 SCC T2bN0M0, IIB
29 M 66 20 SCC T2bN2M0, IIIA
30 M 69 50 SCC T3N0M1a, IV
RT-PCR, reverse-transcriptase polymerase chain reaction; SCC, squamous cell carcinoma.
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we added DLEC1 to Table 3. As we pooled the frozen tissues
from only three patients with SCC, the whole-genome DNA
methylation pattern should be also validated in a number of
tissue samples by methods such as methylation-specific PCR
and pyrosequencing. Subsequently, we validated the DNA
methylation pattern by pyrosequencing under the conditions
listed in Table 4 with 20 SCC samples in which the candidate
genes were significantly down or up-regulated. Therefore, we
have narrowed the list down to five genes (CCDC37, CYTL1,
CDO1, LMO3, and SLIT2) that were hypermethylated and
FIGURE 2. Genes confirmed to be in accordance
with the whole-genome scale combining analysis
in the 30 squamous cell carcinoma (SCC) samples
by semiquantitative reverse-transcriptase polymer-
ase chain reaction (RT-PCR). CCDC37 (A), CYTL1
(B), CDO1 (C), LMO3 (D), and SLIT2 (E) are hyper-
methylated and down-regulated genes in the
whole-genome scale combining assay. SERPINB5
(F) is a hypomethylated and up-regulated gene in
the same assay. DLEC1 (G) is a positive control for
the hypermethylated and down-regulated genes.
SCC1–30 is frozen tissues from patients with
squamous cell carcinoma. N, normal lung tissue;
T, tumor.
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down-regulated and one gene that was hypomethylated and
up-regulated in specific CpG sites of the promoter, as in
Figure 2 and Table 5. The down-regulated genes were proven
to be hypermethylated at their promoter regions in more than
75% of the tested tissue samples. We could identify specific
CpG sites of the promoter that showed apparent differences
of DNA methylation between normal lung and SCC. In
addition, with the aid of pyrosequencing, we could obtain the
data reflecting the quantitative differences of DNA methyl-
ation of specific promoter regions between normal lung and
SCC. As listed in Table 5, we additionally performed the
pyrosequencing using the genomic DNA from 110 SCC
paraffin blocks, and we analyzed these data with Student’s t
test. Through these analyses, we have also confirmed that the
DNA methylation patterns of these six genes were signifi-
cantly different between the normal and tumor tissues. Figure
3 represents the degree of DNA methylation of all the tested
tissues, and we can see the definite differences of the DNA
methylation level between the normal and tumor tissues.
We compared the level of DNA methylation of these
six genes according to the pathologic stage. We found that the
DNA methylation level of the CYTL1 promoter region was
increased with an advanced stage, as shown in Figure 4.
According to TRANSFEC database, CYTL1 (	168) has YY1
transcription binding site (from 	169 to 	173, GGAGC).
Around CYTL1 (	168) region, from 	180 to 	190, many
Sp1 binding sites exist. YY1 interacts with Sp1 and histone
deacetylases (HDACs), which increases repression activity.22
Moreover, CYTL1 (	176 and	192) shows similar pattern in
terms of relationship between disease progression and meth-
ylation. As a matter of fact, the methylation of CYTL1 (	176
and 	192) increased between stages 1 and 2 but not in-
creased between stages 2 and 3 (data not shown). Never-
theless, CYTL1 (	168) hypermethylation seems not to
have an effect on the repression activity by HDACs
through the direct interaction with YY1, because YY1
binding is not affected by CpG methylation.23 Rather,
CYTL1 (	168) hypermethylation in SCC is considered to
be involved in the regulation by HDACs themselves, as
DNA methylation can affect the HDACs’ binding to a
promoter and their functional roles.24,25 Accordingly,
CYTL1 (	168) hypermethylation is likely involved in the
repression activity by HDACs and further related to the
disease progression of SCC.
DNA Methylation Regulates the Expression of
Selected Genes in Lung Cancer
We examined the gene expression of these six genes in
the SCC cell lines using RT-PCR. We found that the results
were consistent with that from the tissue samples (Figure 5A).
To verify whether these genes are regulated by DNA meth-
ylation in specific regions of their promoter, we tested the
demethylation effect on the expression of the five down-
regulated genes. When the cell lines were treated with 5-aza-
2-deoxycytidine, the DNA methylation level of these five
genes was restored, and their expressions were recovered
(Figure 5B). Table 6 lists the DNA methylation level of those
genes before and after treatment with the demethylating agent
in the two SCC cell lines. In this experiment, we could
confirm that the expressions of CCDC37, CYTL1, CDO1,
LMO3, and SLIT2 in SCC are regulated by DNA methylation
on their specific promoter region.
DISCUSSION
DNAmethylation is one of the epigenetic modifications
that does not change the DNA sequence, but it is able to
determine the gene expression by regulating the chromatin
organization.26–28 Epigenetic changes that induce an aberrant
gene expression have been suggested as a cause of tumori-
genesis.29 DNA methylation analysis provides the opportu-
nity for discovering the genes related to tumorigenesis and
developing new target therapies for restoring epigenetic al-
teration. It is no surprise that many researchers are interested
in this area. Costello et al.30 reported a global analysis of the
methylation status of 1184 unselected CpG islands in each of
98 tumor samples using restriction landmark genomic scan-
ning. Since this report, many researchers have investigated
the genome-wide analyses of methylation. Ruike et al.9 per-
formed methylated DNA immunoprecipitation sequencing
(MeDIP-seq) and they obtained the whole-genome DNA
methylation profiles for human breast cancer cells. As an
another example, Cheung et al.10 have used methylated DNA
immunoprecipitation and whole-genome tiling arrays (Me-
DIP-chip) to identify the genes and ncRNA regulated by
DNA methylation in human testicular cancer.
There have also been whole-genome DNA methylation
analyses of lung cancer. Using restriction landmark genomic
scanning, Brena et al.31 found 47-gene methylation signatures
that together could distinguish two lung cancer subgroups,
adenocarcinoma and SCC, and they demonstrated that the
expression of OLIG1 was significantly correlated with the
overall survival of patients with NSCLC. Other frequently
used assays for whole-genome methylation analysis include
expression microarray analysis of cell lines before and after
treatment with DNMT inhibitor and with HDAC inhibitors
(“pharmacological reactivation”), BeadArray-based methyl-
ation analysis of a panel of cancer-related genes (Illumina
GoldenGate methylation assay) and microarray analysis in
combination with immunoprecipitation of methylated DNA
(5-methylcytidine antibody; MeDIP-chip).3 By using the
pharmacological reactivation method, Shames et al.32 re-
ported that ALDH1A3, BNC1, CCNA1, CTSZ, LOX, MSX1,
and NRCAM could be methylated only in lung cancer. Mean-
while, using a sodium bisulfite conversion approach com-
bined with the BeadArray technology, Bibikova et al.33 ana-
lyzed the methylation profiles of 1536 CpG sites from 371
cancer-related genes in cancer cell lines and in lung adeno-
carcinomas. Weber et al.34 established a strategy to isolate
methylated DNA fragments by immunoprecipitation (Me-
DIP) using an anti-5-methylcytidine antibody and they com-
bined the MeDIP assay with the microarray technology (Me-
DIP-chip). Using these high throughput approaches, they
identified genes that were not known to be methylated in lung
cancer, but they realized that in some genes the methylation
pattern by single-gene methylation analysis was different
from those methylation patterns by these high-throughput
approaches. A possible explanation for the differences be-
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tween the two analyses could be that mainly a small number
of samples were used in the high-throughput analyses.3
Therefore, to more accurately reflect the DNA methylation
status, additional validation procedures should be considered
for the whole-genome DNA methylation analysis when using
small numbers of samples.
In this study, by combining the DNA methylation
pattern and the gene expression data, we performed screening
of genes that are possibly regulated by DNA methylation. To
increase the fidelity of the screening results from the whole-
genome scale analysis, we applied a very strict validation
process and we attempted to discover the epigenetically
regulated genes in lung cancer. In addition, we examined the
gene expression level and the methylation pattern of DLEC1,
which had been reported to be hypermethylated in approxi-
mately 40% of NSCLC.21 We also tried to use as many tissue
samples as possible in the validation steps. First, we validated
each gene expression by semiquantitative RT-PCR using 30
tissue samples of SCC and regarded 13 genes as significant
candidates. Compared with methylation-specific PCR, pyro-
sequencing has advantages that it is able to comprehend the
quantitative difference of DNA methylation, and it also
examines all the CpG sites within 100 bp simultaneously.
Therefore, we decided to perform pyrosequencing with 13
genes to more accurately examine the quantitative differences
of DNA methylation. Nevertheless, this technique has disad-
vantage that examination of DNA methylation is impossible
if PCR for a specific region fails. Further, as the quantity of
the specific PCR product is critical for pyrosequencing, some
samples with a PCR product less than the minimal require-
ment were excluded from the pyrosequencing. As a result, we
were able to identify six genes (CCDC37, CYTL1, CDO1,
SERPINB5, LMO3, and SLIT2) and find which CpG site of
the promoter region was significantly hyper or hypomethy-
FIGURE 3. Differences in DNA methylation between normal lung and squamous cell carcinoma (SCC). These graphs show
the DNA methylation pattern of CCDC37 (A), CYTL1 (B), LMO3 (C), and SERPINB5 (D) in both normal lung and SCC. Four
genes among the selected six genes were confirmed to have different DNA methylation patterns as compared between nor-
mal lung and SCC. In detail, CCDC37, CYTL1, and LMO3 were hypermethylated, and SERPINB5 was hypomethylated in SCC.
Each dot represents the DNA methylation of each sample, which was from frozen tissue or a paraffin block. For statistical anal-
ysis, Student’s t test was applied, and p values 0.05 were considered to be significant. The promoter region (the transcrip-
tion start site is 	1) was examined, and the mean value and standard error of the mean of the normal lung and lung cancer
are also depicted. Each graph displays the number of samples used and qualified by pyrosequencing. Although the DNA
methylation of 20 SCC samples was examined by pyrosequencing, each graph has different sample numbers because of the
quality check for pyrosequencing. In each panel, the upper three graphs and lower three graphs are the results from the fro-
zen tissues and SCC paraffin blocks, respectively. In the lower three graphs in each panel, the dotted line means the DNA
methylation level of the purified epithelial cells of the representative normal lung.
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lated. After that, to increase the accuracy of the results, we
performed additional pyrosequencing for these six genes with
110 paraffin block samples. In this experiment, we used
normal bronchial epithelial cells as a normal control for the
SCC paraffin block samples, and we used the method we
reported in 2008.35 With this process, we could confirm the
similar DNA methylation pattern with those from the 20
frozen tissue samples in four genes: CCDC37, CYTL1,
LMO3, and SERPINB5. On the other hand, two genes, CDO1
and SLIT2, showed different results from that of the 20 frozen
tissue samples, as is presented in Table 5. CDO1 had different
ratios at each CpG site between the frozen tissue samples and
the paraffin block samples, whereas SLIT2 had reduced ratios
at all the CpG sites compared with that of the frozen tissue
samples. This might have resulted from the fact that the 20
frozen tissue samples were not enough to reflect the accurate
ratio of hypermethylation of those two genes.
We used the SCC cell lines to examine whether the
expression level and DNA methylation pattern of the five
genes are restored by a demethylating agent. As we treated
these cell lines with 5-aza-2-deoxycytidines, we could see
the restoration of DNA methylation of the five genes that
were originally hypermethylated. Therefore, we could iden-
tify that DNA methylation of specific CpG sites of the
promoter region affects the gene expression of the five genes,
and the five genes showed the difference of the methylation
pattern between normal individuals and patients with SCC, as
they are shown in Figure 2 and Table 5, respectively.
Herein, we identified six genes regulated by DNA
methylation. Among them, three genes (LMO3, SERPINB5,
and SLIT2) have been reported to be related to lung cancer.
LMO3 belongs to the LIM-only protein family, and it is
known to be down-regulated in SCC of the lung.36,37 Our data
also showed that LMO3, which was down-regulated in 23 of
30 SCC samples, was hypermethylated in SCC. LMO3 has
been reported to regulate the expression of p53 dependent
genes in neuroblastoma by interacting with p53,38 and it is
involved in cell proliferation by interacting with HEN2, a
neuronal transcription factor, within a nucleus. Nevertheless,
since nothing has been revealed about the function of LMO3
and its binding partner in lung cancer, it is necessary to
unveil the role of LMO3 and define the signaling pathway
involved with DNA methylation of LMO3. SERPINB5 is a
tumor suppressor protein that has been shown to inhibit
tumor progression and metastasis.39 According to our data,
SERPINB5 was hypomethylated and up-regulated in SCC.
In addition, the aberrant hypomethylation of SERPINB5 is
FIGURE 4. The correlation of DNA methylation of CYTL1
with the squamous cell carcinoma (SCC) stages. The DNA
methylation level of CYTL1 (	168) was compared after di-
viding the samples according to their pathologic stage. The
difference of the DNA methylation levels was 6.49 between
stage I and stage II and 4.38 between stage II and stage III.
Their p value of one-way analysis of variance (ANOVA) analy-
sis was 0.0471. Therefore, the CpG site (	168) of the CYTL1
promoter region was recognized as a hot spot that has cor-
relation with the SCC stage. The dotted line is the DNA
methylation level of normal lung.
FIGURE 5. Restoration of the gene expression by 5-aza-2-deoxycytidine treatment in the SCC cell lines. A, The total RNA
was extracted from the normal lung tissues and two SCC cell lines, and the complementary DNAs (cDNAs) were synthesized.
By using the cDNA as a template, semiquantitative RT-PCR was done, and GAPDH was used as a loading control. CCDC37,
CDO1, LMO3, CYTL1, and SLIT2 were down-regulated, and SERPINB5 was up-regulated in the SCC cell lines in accordance
with the data from the tissue samples. B, To validate whether these results were caused by DNA methylation, 5-aza-2-deoxy-
cytidine treatment was performed in the SCC cell lines. The SCC cell lines were treated with a demethylating agent (20 M
5-aza-2-deoxycytidine) for 4 days, and the expression levels of the five genes that were found to be hypermethylated in the
previous experiment were recovered to their original expression level in the SCC cell lines. SCC-13N and SCC-15N: normal
lung tissue; HCC-95, HCC-1588, Calu-1, SK-MES-1, and SW900: squamous cell carcinoma cell lines.
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frequently observed in human melanoma cell lines.40 Taken
together, it seems that SERPINB5, when hypomethylated and
up-regulated, functions as a tumor suppressor in SCC of the
lung. This is supported by the fact that SERPINB5 reduces
the phosphorylation of Akt.39 SERPINB5 has been reported
to be an endogenous inhibitor of histone deacetylase 1
(HDAC1).41 We assume that it might induce the expression
of other tumor suppressor genes. In case of SLIT2, several
reports have shown similar results as our data. Dallol et al.
reported that SLIT2 is frequently inactivated in breast cancer,
colorectal cancer, lung cancer, and glioma by hypermethyl-
ation of the CpG islands in its promoter region,42–44 and Jin
et al.45–47 demonstrated that it might be useful as a therapeu-
tic target for the treatment of human hepatocellular carci-
noma. It was reported that the expression of SLIT2 was
restored in hepatoma cell lines with a low expression after
treatment with 5-aza-2-deoxycytidine.46 Our results suggest
that deregulation of SLIT2 by hypermethylation might be
associated with the development and progression of SCC. It
was recently revealed that SLIT2 attenuation during lung
cancer progression deregulates beta-catenin and E-cadherin,
and this is associated with a poor prognosis.47,48 We need
more studies on the functions of SLIT2 and its related
pathways to more concretely understand how it functions in
lung cancer development.
On the other hand, three genes (CDO1, CYTL1, and
CCDC37) have not been well studied in lung cancer. There
was a report that methylation of CDO1 was a predictive
factor for distant metastasis in patients with lymph node-
positive/estrogen receptor-positive breast cancer who under-
went anthracycline-based chemotherapy.49 Similarly, our
data showed that CDO1 was hypermethylated and down-
regulated in lung cancer. In addition, we found its expression
level and methylation pattern were recovered after treatment
with a demethylating agent.
In summary, SLIT2, DLEC1, and LMO3 showed down-
regulation and hypermethylation, and SERPINB5 showed
up-regulation and hypomethylation in SCC. Nevertheless,
TABLE 6. Restoration of the DNA Methylation Level in the Specific CpG Sites Residing in the Promoter Region of Each Gene
After 5-Aza-2-Deoxycytidine Treatment in the Two SCC Cell Lines
Cell Line
Hypermethylation
CCDC37 CYTL1_1 CYTL1_3
324 307 302 263 81 72 48 143 145 168 176 188 192
95 8 39 4 88 32 21 39 94 83 100 93 90 44
95	 6 40 3 78 25 15 36 77 68 69 75 77 20
Difference 2 1 1 10 7 6 3 17 15 31 18 13 24
1588 86 92 80 85 29 24 35 67 57 95 82 82 30
1588	 59 78 50 81 17 15 27 61 54 67 74 62 22
Difference 27 14 30 4 12 9 8 6 3 28 8 20 8
Cell Line
Hypermethylation
CDO1
172 170 161 159 146 143 134 117 115 108 99 89 87 80
95 39 40 62 40 54 71 49 59 30 96 73 59 50 100
95	 36 34 60 37 48 65 46 52 27 89 65 54 40 61
Difference 3 6 2 3 6 6 3 7 3 7 8 5 10 39
1588 40 18 67 35 56 63 50 58 25 88 82 54 33 76
1588	 35 13 53 23 43 44 42 51 17 73 67 46 28 63
Difference 5 5 14 12 13 19 8 7 8 15 15 8 5 13
Cell Line
Hypermethylation
LMO3 SLIT2
626 618 610 568 239 257 278 284
95 89 91 89 82 30 38 60 68
95	 69 72 69 55 25 29 57 62
Difference 20 19 20 27 5 9 3 6
1588 94 93 94 92 21 28 55 69
1588	 66 75 67 63 18 23 55 65
Difference 28 18 27 29 3 5 0 4
In the two SCC cell lines, HCC-95 and HCC-1588, the DNA methylation levels of all five genes were restored by treatment with a demethylating agent 5-aza-2-deoxycytidine.
These results provided the evidence that these five genes could be regulated by DNA methylation and the information about which CpG sites are methylated is critical for that
regulation.
SCC, squamous cell carcinoma.
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two genes, CCDC37 and CYTL1, have not been well studied
as to their functions in lung cancer. So, we think we need
further study of those genes. CYTL1 is known to control
chondrogenesis of mesenchymal cells, and its expression was
also reported to be quite decreased in mesenchymal cells.50
Accordingly, we can speculate that CYTL1 might be involved
in the tumorigenesis of lung cancer as its expression is
suppressed during the epithelial to mesenchymal cell transi-
tion. We are attempting to get some solid clues about the
function of CCDC37 by examining cell proliferation and
invasion when this gene is overexpressed (the data are not
shown here).
We combined the whole-genome DNA methylation
pattern and the gene expression profile specific to SCC of
the lung. Through this analysis, we proved this method is
very effective in finding genes regulated by DNA methyl-
ation, and we found six genes (CCDC37, CYTL1, CDO1,
SLIT2, LMO3, and SERPINB5) in SCC of the lung. We
hope that this result can contribute to the development of
a new method for the early detection and prevention of
lung cancer.
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